ABBY MELANCON: Open Payments
NPI 1902534035 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 26 payments from 9 companies in 2025. Trend: 2023 $135 · 2024 $309 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $264 |
| Genentech USA, Inc. | 5 | $101 |
| Incyte Corporation | 3 | $76 |
| Celgene Corporation | 3 | $58 |
| Merck Sharp & Dohme LLC | 2 | $40 |
| Karyopharm Therapeutics Inc. | 2 | $31 |
| Legend Biotech USA Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Invivyd Inc | 1 | $19 |
Products named: TECVAYLI, RYBREVANT, Venclexta, BREYANZI, JAKAFI, PREVYMIS, Polivy, XPOVIO.
Industry payments across MS — which companies pay providers there.
